Lion Point Capital »

Humacyte shares owned by Lion Point Capital

Quarter-by-quarter ownership of Humacyte (HUMA) shares owned by Lion Point Capital from 13F filings

Historical chart of Lion Point Capital investment in Humacyte

Tip: Access up to 7 years of quarterly data

All positions including Humacyte held by Lion Point Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Humacyte by Lion Point Capital

Quarter filed Position value Share count Share price at filing
2023-12-31 $667k 235k 2.84
2023-09-30 $689k 235k 2.93

More positions owned by Lion Point Capital

Semtech Corporation (SMTC)
Ishares Tr Russell 2000 Etf Put Option (IWM)
Marinus Pharmaceuticals Com New (MRNS)
Ardelyx (ARDX)
Milestone Pharmaceuticals (MIST)
Harpoon Therapeutics Com New
Burgerfi International (BFI)
Kiniksa Pharmaceuticals Com Cl A (KNSA)
Insmed Com Par $.01 (INSM)
Battalion Oil Corp (BATL)
Cymabay Therapeutics
Fennec Pharmaceuticals (FENC)
Avadel Pharmaceuticals Sponsored Adr (AVDL)
Enphys Acquisition Corp Cl A Ord Shs (NFYS)
Syndax Pharmaceuticals (SNDX)

View all positions for Lion Point Capital

Top funds holding Humacyte

Vanguard Group
Millennium Management
Prescott General Partners
Charles Schwab Investment Management
GSA Capital Partners
Two Sigma Investments
Private Advisor
Capstone Investment Advisors
Citadel Advisors
Lion Point Capital
United Asset Strategies
Marshall Wace
Bank of New York Mellon
Clough Capital Partners
Goldman Sachs Group

View all funds holding Humacyte